The impact of newer antidiabetic medications like sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP4) inhibitors on bone health and DM remains uncertain, as there is insufficient data available (21). The gene discussed is DPP4; the disease is diabetes mellitus.